Procter & Gamble Health Limited (formerly Merck Limited) announced today its financial results for the half year ended December 31, 2020. The company has recorded a total sale of ₹ 238 crores for the quarter ended December 31, 2020, up 3% vs year ago. The Profit After Tax (PAT) was ₹ 68 crores vs ₹ 38 crores year ago, driven primarily by lower travel and selling expenses due to Covid-19 pandemic. Sales for the six-month period ending December 31, 2020 were ₹ 496 crores, up by 10% vs year ago. Profit After Tax for same period was ₹ 127 Crore.
Milind Thatte, Managing Director, Procter & Gamble Health Limited said, "The Company continues to deliver consistent sales growth driven by a sustained demand for our quality and affordable vitamins, minerals, supplements and medicinal products. With the country gradually opening up and the markets showing a steady recovery in the health category, we will continue our focus on ensuring uninterrupted supplies while doubling down our efforts to increase reach through scientific communication, portfolio consumerization, and disease awareness and education. Our 'SEHAT' (meaning Health) Corporate Social Responsibility (CSR) initiative continues to grow from strength-to strength with a host of programs dedicated to public health; ranging from building capability and capacity at grassroots, to supporting vulnerable and disadvantaged populations through our partner NGOs."
Shares of Procter & Gamble Health Limited was last trading in BSE at Rs.7350 as compared to the previous close of Rs. 7315.15. The total number of shares traded during the day was 995 in over 395 trades.
The stock hit an intraday high of Rs. 7450 and intraday low of 7257.65. The net turnover during the day was Rs. 7288464.